PT-141 brought a small desire gain and frequent nausea
Scientists made the drug after tanning work brought an unexpected sexual response. Later studies followed the benefit, the harms, and its time in blood.
- prescription peptide noun phrase
- A medicine dispensed against a clinician's written order.
- In use:
Promise Peptides prescribes PT-141 (bremelanotide) today. Its product at mypromise.com requires a clinician's prescription.
A clinician with a U.S. license judges the case and can refuse. For patients outside the U.S., the service is unavailable. Within the U.S., both state and treatment constrain the offer. FDA approval does not extend to compounded preparations.
Women gained a little desire, but nausea was common
Researchers were seeking a tanning drug when an unexpected sexual effect appeared; they made PT-141 to study that effect. Its drug name is bremelanotide, and it is a peptide, a short chain of protein parts. The medicine changes activity in parts of the brain that help govern sexual interest and hunger [1].
The US drug agency approved the shot for women who haven't gone through menopause. Their loss of desire must have started later, happen in every setting, and cause distress [7]. No other use has approval; studies of men and older women were smaller and didn't support approval [7].
In the women's trials, women reported a slight lift in desire that lasted through one year [3][4]. Nausea was the main harm, and about four in ten long-term users felt sick [4]. A shot can briefly push blood pressure upward. The label bars the drug for poorly controlled high blood pressure [7]. The PT-141 effects page gives you the full warning list.
A bottle sold online for lab research is not the approved drug; no drug agency checks its quality [12].
The Field Reports page helps you keep personal posts apart from fair trial results.
PT-141 was built as a small ring
PT-141 contains seven amino acids joined in a ring; amino acids are small parts used to make proteins. Researchers based the drug on a hormone that carries instructions between cells [1]. The ring form slows its breakdown. A laboratory weight cannot tell you whether a medicine is safe or useful.
The PT-141 peptide acts at two places in the brain that help control desire and hunger [1]. Bremelanotide is the standard drug name, while a related substance had been made for tanning. The newer drug was designed so researchers could study desire instead.
In rats and monkeys, bremelanotide caused erections, and brain cells that help guide desire became more active [1]. Those findings point to an effect in the brain. PDE-5 inhibitors is the medical name for common erection pills. Those pills ease muscles around blood vessels; this peptide does not [7].
Two large trials found only a small desire gain
Two Phase 3 trials, the large tests used before approval, included 1,267 women before menopause. Each woman was troubled by lasting low desire [3]. After 24 weeks, the women said their desire had risen slightly, and low desire troubled them less. Question 13 asked how often that problem bothered them. For desire, the paper's chance mark was below .001; it was also below .001 for distress. In plain words, chance alone was a poor answer. Both changes were greater than with placebo, an inactive shot used for a fair test [3].
A 52-week study then followed 684 women; the small benefit persisted, and researchers saw no new harm [4]. A separate scan study of 31 women found more desire for up to 24 hours. After the shot, areas of the brain used in sexual response reacted differently to sexual images [5].
The improvement remained modest. A paper that combined many trials found placebo made up about 67.7% of the measured change [13]. Doctors still debate whether the drug makes enough difference in your daily life [9].
The blood level fell by half within a few hours
After a shot beneath the skin, half the drug remained in blood about 2.7 hours later. This span is called the half-life; across the people tested, it took 1.9–4.0 hours [7]. The PT-141 half life page explains the other times. The PT-141 effects page covers nausea, flushing, headaches, darker skin, and higher blood pressure. The PT-141 research page shows you which amounts were studied.
Studies point to a change in the brain's control of sexual interest [1][7]. The label also explains how the drug travels through the body and leaves it. Much is still unknown; these trials don't support use beyond women with distressing low desire before menopause. Doctors also dispute the value of the small gain. Vials bearing the words "for research" add risk because no drug agency checks them [9][12].